Treatment options for multidrug-resistant nonfermenters

References

• Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin. Infect. Dis.46(7), 1121–1122 (2008).
   PubMed Web of Science ®Google Scholar
• Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extended-spectrum-β-lactamase-producing Enterobacteriaceae. Antimicrob. Agents Chemother.50(4), 1257–1262 (2006).
   PubMed Web of Science ®Google Scholar
• Lee SY, Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Impact of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect. Control Hosp. Epidemiol.27(11), 1226–1232 (2006).
   PubMed Web of Science ®Google Scholar
• Critchley IA, Karlowsky JA. Optimal use of antibiotic resistance surveillance systems. Clin. Microbiol. Infect.10(6), 502–511 (2004).
   PubMedGoogle Scholar
• Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis.48(1), 1–12 (2009).
   PubMed Web of Science ®Google Scholar
• Rice LB. Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin. Infect. Dis.43(Suppl. 2), S100–S105 (2006).
   PubMed Web of Science ®Google Scholar
• Jones RN. Resistance patterns among nosocomial pathogens: trends over the past few years. Chest119(2 Suppl.), S397–S404 (2001).
   PubMed Web of Science ®Google Scholar
• Govan JR, Nelson JW. Microbiology of lung infection in cystic fibrosis. Br. Med. Bull.48(4), 912–930 (1992).
   PubMed Web of Science ®Google Scholar
• Spencker FB, Haupt S, Claros MC et al. Epidemiologic characterization of Pseudomonas aeruginosa in patients with cystic fibrosis. Clin. Microbiol. Infect.6(11), 600–607 (2000).
   PubMed Web of Science ®Google Scholar
• Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features and trends in the SENTRY Antimicrobial Surveillance Program (1997–1999). Clin. Infect. Dis.32(Suppl. 2), S104–S113 (2001).
   PubMed Web of Science ®Google Scholar
• McGowan JE Jr. Resistance in nonfermenting Gram-negative bacteria: multidrug resistance to the maximum. Am. J. Med.119(6 Suppl. 1), S29–S36 (2006).
   PubMed Web of Science ®Google Scholar
• Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit. Care Med.27(5), 887–892 (1999).
   PubMed Web of Science ®Google Scholar
• Jain R, Danziger LH. Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann. Pharmacother.38(9), 1449–1459 (2004).
   PubMed Web of Science ®Google Scholar
• Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis.39(3), 309–317 (2004).
   PubMed Web of Science ®Google Scholar
• Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother.39(6), 1211–1233 (1995).
   PubMed Web of Science ®Google Scholar
• Strateva T, Yordanov D. Pseudomonas aeruginosa – a phenomenon of bacterial resistance. J. Med. Microbiol.58(Pt 9), 1133–1148 (2009).
   PubMed Web of Science ®Google Scholar
• Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin. Microbiol. Rev.22(4), 582–610 (2009).
   PubMed Web of Science ®Google Scholar
• Henrichfreise B, Wiegand I, Pfister W, Wiedemann B. Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation. Antimicrob. Agents Chemother.51(11), 4062–4070 (2007).
   PubMed Web of Science ®Google Scholar
• Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol. Mol. Biol. Rev.67(4), 593–656 (2003).
   PubMed Web of Science ®Google Scholar
• Quinn JP, Darzins A, Miyashiro D, Ripp S, Miller RV. Imipenem resistance in Pseudomonas aeruginosa PAO: mapping of the OprD2 gene. Antimicrob. Agents Chemother.35(4), 753–755 (1991).
   PubMedGoogle Scholar
• Acar JF. Therapy for lower respiratory tract infections with imipenem/cilastatin: a review of worldwide experience. Rev. Infect. Dis.7(Suppl. 3), S513–S517 (1985).
   PubMedGoogle Scholar
• Stover CK, Pham XQ, Erwin AL et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature406(6799), 959–964 (2000).
   PubMed Web of Science ®Google Scholar
• Li Y, Mima T, Komori Y et al. A new member of the tripartite multidrug efflux pumps, MexVW-OprM, in Pseudomonas aeruginosa. J. Antimicrob. Chemother.52(4), 572–575 (2003).
   PubMedGoogle Scholar
• Ochs MM, McCusker MP, Bains M, Hancock RE. Negative regulation of the Pseudomonas aeruginosa outer membrane porin OprD selective for imipenem and basic amino acids. Antimicrob. Agents Chemother.43(5), 1085–1090 (1999).
   PubMed Web of Science ®Google Scholar
• Livermore DM. Interplay of impermeability and chromosomal β-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother.36(9), 2046–2048 (1992).
   PubMed Web of Science ®Google Scholar
• Picao RC, Poirel L, Gales AC, Nordmann P. Diversity of β-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolates causing bloodstream infections in Brazil. Antimicrob. Agents Chemother.53(9), 3908–3913 (2009).
   PubMed Web of Science ®Google Scholar
• Ambler RP. The structure of β-lactamases. Philos. Trans. R. Soc. Lond. B Biol. Sci.289(1036), 321–331 (1980).
   PubMed Web of Science ®Google Scholar
• Mansour W, Dahmen S, Poirel L et al. Emergence of SHV-2a extended-spectrum β-lactamases in clinical isolates of Pseudomonas aeruginosa in a university hospital in Tunisia. Microb. Drug Resist.15(4), 295–301 (2009).
   PubMedGoogle Scholar
• Viedma E, Juan C, Acosta J et al. Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum β-lactamases GES-1 and GES-5 in Spain. Antimicrob. Agents Chemother.53(11), 4930–4933 (2009).
   PubMed Web of Science ®Google Scholar
• Juan C, Mulet X, Zamorano L, Alberti S, Perez JL, Oliver A. Detection of the novel extended-spectrum β-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain. Antimicrob. Agents Chemother.53(12), 5288–5290 (2009).
   PubMed Web of Science ®Google Scholar
• Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-β-lactamases: the quiet before the storm? Clin. Microbiol. Rev.18(2), 306–325 (2005).
   PubMed Web of Science ®Google Scholar
• Garza-Ramos U, Tinoco P, Rojas T et al. Molecular characterization of integron class 1 (In196) encoding the VIM-2 metallo-β-lactamase of Pseudomonas aeruginosa isolated from a hospital environment. J. Chemother.21(5), 590–591 (2009).
   PubMed Web of Science ®Google Scholar
• Azucena E, Mobashery S. Aminoglycoside-modifying enzymes: mechanisms of catalytic processes and inhibition. Drug Resist. Updat.4(2), 106–117 (2001).
   PubMedGoogle Scholar
• Kim C, Villegas-Estrada A, Hesek D, Mobashery S. Mechanistic characterization of the bifunctional aminoglycoside-modifying enzyme AAC(3)-Ib/AAC(6’)-Ib’ from Pseudomonas aeruginosa. Biochemistry46(17), 5270–5282 (2007).
   PubMedGoogle Scholar
• Zeng L, Jin S. Aph(3’)-IIb, a gene encoding an aminoglycoside-modifying enzyme, is under the positive control of surrogate regulator HpaA. Antimicrob. Agents Chemother.47(12), 3867–3876 (2003).
   PubMedGoogle Scholar
• Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerg. Infect. Dis.7(2), 337–341 (2001).
   PubMed Web of Science ®Google Scholar
• Lee JK, Lee YS, Park YK, Kim BS. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa. Int. J. Antimicrob. Agents25(4), 290–295 (2005).
   PubMed Web of Science ®Google Scholar
• Tran JH, Jacoby GA. Mechanism of plasmid-mediated quinolone resistance. Proc. Natl Acad. Sci. USA99(8), 5638–5642 (2002).
   PubMed Web of Science ®Google Scholar
• Jacoby GA. Mechanisms of resistance to quinolones. Clin. Infect. Dis.41(Suppl. 2), S120–S126 (2005).
   PubMed Web of Science ®Google Scholar
• Van LM, Goossens H. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin. Microbiol. Infect.10(8), 684–704 (2004).
   PubMedGoogle Scholar
• Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev.21(3), 538–582 (2008).
   PubMed Web of Science ®Google Scholar
• Clark RB. Imipenem resistance among Acinetobacter baumannii: association with reduced expression of a 33–36 kDa outer membrane protein. J. Antimicrob. Chemother.38(2), 245–251 (1996).
   PubMed Web of Science ®Google Scholar
• Quale J, Bratu S, Landman D, Heddurshetti R. Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City. Clin. Infect. Dis.37(2), 214–220 (2003).
   PubMed Web of Science ®Google Scholar
• Limansky AS, Mussi MA, Viale AM. Loss of a 29-kilodalton outer membrane protein in Acinetobacter baumannii is associated with imipenem resistance. J. Clin. Microbiol.40(12), 4776–4778 (2002).
   PubMedGoogle Scholar
• Bou G, Cervero G, Dominguez MA, Quereda C, Martinez-Beltran J. Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumannii is not due solely to the presence of β-lactamases. J. Clin. Microbiol.38(9), 3299–3305 (2000).
   PubMed Web of Science ®Google Scholar
• Gribun A, Nitzan Y, Pechatnikov I, Hershkovits G, Katcoff DJ. Molecular and structural characterization of the HMP-AB gene encoding a pore-forming protein from a clinical isolate of Acinetobacter baumannii. Curr. Microbiol.47(5), 434–443 (2003).
   PubMed Web of Science ®Google Scholar
• Magnet S, Courvalin P, Lambert T. Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrob. Agents Chemother.45(12), 3375–3380 (2001).
   PubMed Web of Science ®Google Scholar
• Marchand I, Damier-Piolle L, Courvalin P, Lambert T. Expression of the RND-type efflux pump AdeABC in Acinetobacter baumannii is regulated by the AdeRS two-component system. Antimicrob. Agents Chemother.48(9), 3298–3304 (2004).
   PubMed Web of Science ®Google Scholar
• Lin L, Ling BD, Li XZ. Distribution of the multidrug efflux pump genes, adeABC, adeDE and adeIJK, and class 1 integron genes in multiple-antimicrobial-resistant clinical isolates of Acinetobacter baumannii – Acinetobacter calcoaceticus complex. Int. J. Antimicrob. Agents33(1), 27–32 (2009).
   PubMed Web of Science ®Google Scholar
• Joly-Guillo ML, Vallee E, Bergogne-Berezin E, Philippon A. Distribution of β-lactamases and phenotype analysis in clinical strains of Acinetobacter calcoaceticus. J. Antimicrob. Chemother.22(5), 597–604 (1988).
   PubMedGoogle Scholar
• Blechschmidt B, Borneleit P, Kleber HP. Purification and characterization of an extracellular β-lactamase produced by Acinetobacter calcoaceticus. J. Gen. Microbiol.138(6), 1197–1202 (1992).
   PubMedGoogle Scholar
• Corvec S, Caroff N, Espaze E, Giraudeau C, Drugeon H, Reynaud A. AmpC cephalosporinase hyperproduction in Acinetobacter baumannii clinical strains. J. Antimicrob. Chemother.52(4), 629–635 (2003).
   PubMed Web of Science ®Google Scholar
• Mammeri H, Poirel L, Mangeney N, Nordmann P. Chromosomal integration of a cephalosporinase gene from Acinetobacter baumannii into Oligella urethralis as a source of acquired resistance to β-lactams. Antimicrob. Agents Chemother.47(5), 1536–1542 (2003).
   PubMedGoogle Scholar
• Lopez-Hernandez S, Alarcon T, Lopez-Brea M. Biochemical characterization of chromosomal cephalosporinases from isolates belonging to the Acinetobacter baumannii complex. Clin. Microbiol. Infect.7(4), 218–226 (2001).
   PubMedGoogle Scholar
• Beceiro A, Dominguez L, Ribera A et al. Molecular characterization of the gene encoding a new AmpC β-lactamase in a clinical strain of Acinetobacter genomic species 3. Antimicrob. Agents Chemother.48(4), 1374–1378 (2004).
   PubMedGoogle Scholar
• Perilli M, Felici A, Oratore A et al. Characterization of the chromosomal cephalosporinases produced by Acinetobacter lwoffii and Acinetobacter baumannii clinical isolates. Antimicrob. Agents Chemother.40(3), 715–719 (1996).
   PubMed Web of Science ®Google Scholar
• Bou G, Martinez-Beltran J. Cloning, nucleotide sequencin, and analysis of the gene encoding an AmpC β-lactamase in Acinetobacter baumannii. Antimicrob. Agents Chemother.44(2), 428–432 (2000).
   PubMed Web of Science ®Google Scholar
• Hujer KM, Hamza NS, Hujer AM et al. Identification of a new allelic variant of the Acinetobacter baumannii cephalosporinase, ADC-7 β-lactamase: defining a unique family of class C enzymes. Antimicrob. Agents Chemother.49(7), 2941–2948 (2005).
   PubMed Web of Science ®Google Scholar
• Mak JK, Kim MJ, Pham J, Tapsall J, White PA. Antibiotic resistance determinants in nosocomial strains of multidrug-resistant Acinetobacter baumannii. J. Antimicrob. Chemother.63(1), 47–54 (2009).
   PubMed Web of Science ®Google Scholar
• Vila J, Marcos A, Marco F et al.In vitro antimicrobial production of β-lactamases, aminoglycoside-modifying enzymes and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii. Antimicrob. Agents Chemother.37(1), 138–141 (1993).
   PubMed Web of Science ®Google Scholar
• Huang ZM, Mao PH, Chen Y, Wu L, Wu J. [Study on the molecular epidemiology of SHV type β-lactamase-encoding genes of multiple-drug-resistant Acinetobacter baumannii]. Zhonghua Liu Xing Bing Xue Za Zhi25(5), 425–427 (2004).
   PubMedGoogle Scholar
• Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin. Microbiol. Rev.9(2), 148–165 (1996).
   PubMed Web of Science ®Google Scholar
• Nagano N, Nagano Y, Cordevant C, Shibata N, Arakawa Y. Nosocomial transmission of CTX-M-2 β-lactamase-producing Acinetobacter baumannii in a neurosurgery ward. J. Clin. Microbiol.42(9), 3978–3984 (2004).
   PubMed Web of Science ®Google Scholar
• Vahaboglu H, Ozturk R, Aygun G et al. Widespread detection of PER-1-type extended-spectrum β-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrob. Agents Chemother.41(10), 2265–2269 (1997).
   PubMed Web of Science ®Google Scholar
• Yong D, Shin JH, Kim S et al. High prevalence of PER-1 extended-spectrum β-lactamase-producing Acinetobacter spp. in Korea. Antimicrob. Agents Chemother.47(5), 1749–1751 (2003).
   PubMed Web of Science ®Google Scholar
• Poirel L, Karim A, Mercat A et al. Extended-spectrum β-lactamase-producing strain of Acinetobacter baumannii isolated from a patient in France. J. Antimicrob. Chemother.43(1), 157–158 (1999).
   PubMedGoogle Scholar
• Poirel L, Menuteau O, Agoli N, Cattoen C, Nordmann P. Outbreak of extended-spectrum β-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a French hospital. J. Clin. Microbiol.41(8), 3542–3547 (2003).
   PubMed Web of Science ®Google Scholar
• Carbonne A, Naas T, Blanckaert K et al. Investigation of a nosocomial outbreak of extended-spectrum β-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a hospital setting. J. Hosp. Infect.60(1), 14–18 (2005).
   PubMed Web of Science ®Google Scholar
• Navia MM, Ruiz J, Vila J. Characterization of an integron carrying a new class D β-lactamase (OXA-37) in Acinetobacter baumannii. Microb. Drug Resist.8(4), 261–265 (2002).
   PubMedGoogle Scholar
• Vila J, Navia M, Ruiz J, Casals C. Cloning and nucleotide sequence analysis of a gene encoding an OXA-derived β-lactamase in Acinetobacter baumannii. Antimicrob. Agents Chemother.41(12), 2757–2759 (1997).
   PubMedGoogle Scholar
• Poirel L, Gerome P, De CC, Stephanazzi J, Naas T, Nordmann P. Integron-located oxa-32 gene cassette encoding an extended-spectrum variant of OXA-2 β-lactamase from Pseudomonas aeruginosa. Antimicrob. Agents Chemother.46(2), 566–569 (2002).
   PubMed Web of Science ®Google Scholar
• Poirel L, Girlich D, Naas T, Nordmann P. OXA-28, an extended-spectrum variant of OXA-10 β-lactamase from Pseudomonas aeruginosa and its plasmid- and integron-located gene. Antimicrob. Agents Chemother.45(2), 447–453 (2001).
   PubMed Web of Science ®Google Scholar
• Zarrilli R, Crispino M, Bagattini M et al. Molecular epidemiology of sequential outbreaks of Acinetobacter baumannii in an intensive care unit shows the emergence of carbapenem resistance. J. Clin. Microbiol.42(3), 946–953 (2004).
   PubMed Web of Science ®Google Scholar
• Yum JH, Yi K, Lee H et al. Molecular characterization of metallo-β-lactamase-producing Acinetobacter baumannii and Acinetobacter genomospecies 3 from Korea: identification of two new integrons carrying the bla(VIM-2) gene cassettes. J. Antimicrob. Chemother.49(5), 837–840 (2002).
   PubMedGoogle Scholar
• Lee K, Ha GY, Shin BM et al. Metallo-β-lactamase-producing Gram-negative bacilli in Korean Nationwide Surveillance of Antimicrobial Resistance group hospitals in 2003: continued prevalence of VIM-producing Pseudomonas spp. and increase of IMP-producing Acinetobacter spp. Diagn. Microbiol. Infect. Dis.50(1), 51–58 (2004).
   PubMedGoogle Scholar
• Lee K, Yum JH, Yong D et al. Novel acquired metallo-β-lactamase gene, bla(SIM-1), in a class 1 integron from Acinetobacter baumannii clinical isolates from Korea. Antimicrob. Agents Chemother.49(11), 4485–4491 (2005).
   PubMed Web of Science ®Google Scholar
• Seward RJ, Lambert T, Towner KJ. Molecular epidemiology of aminoglycoside resistance in Acinetobacter spp. J. Med. Microbiol.47(5), 455–462 (1998).
   PubMedGoogle Scholar
• Nemec A, Dolzani L, Brisse S, van den Broek P, Dijkshoorn L. Diversity of aminoglycoside-resistance genes and their association with class 1 integrons among strains of pan-European Acinetobacter baumannii clones. J. Med. Microbiol.53(Pt 12), 1233–1240 (2004).
   PubMed Web of Science ®Google Scholar
• Vila J, Ruiz J, Goni P, Marcos A, Jimenez de AT. Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii. Antimicrob. Agents Chemother.39(5), 1201–1203 (1995).
   PubMed Web of Science ®Google Scholar
• Vila J, Ruiz J, Goni P, Jimenez de AT. Quinolone-resistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii. J. Antimicrob. Chemother.39(6), 757–762 (1997).
   PubMedGoogle Scholar
• Nordmann P, Poirel L. Emergence of plasmid-mediated resistance to quinolones in Enterobacteriaceae. J. Antimicrob. Chemother.56(3), 463–469 (2005).
   PubMed Web of Science ®Google Scholar
• Hanson ND, Hossain A, Buck L, Moland ES, Thomson KS. First occurrence of a Pseudomonas aeruginosa isolate in the United States producing an IMP metallo-β-lactamase, IMP-18. Antimicrob. Agents Chemother.50(6), 2272–2273 (2006).
   PubMed Web of Science ®Google Scholar
• Lolans K, Queenan AM, Bush K, Sahud A, Quinn JP. First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-β-lactamase (VIM-2) in the United States. Antimicrob. Agents Chemother.49(8), 3538–3540 (2005).
   PubMed Web of Science ®Google Scholar
• Deplano A, Denis O, Poirel L et al. Molecular characterization of an epidemic clone of panantibiotic-resistant Pseudomonas aeruginosa. J. Clin. Microbiol.43(3), 1198–1204 (2005).
   PubMed Web of Science ®Google Scholar
• Pillar CM, Torres MK, Brown NP, Shah D, Sahm DF. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by Gram-negative bacteria, against recent clinical isolates from the United States. Antimicrob. Agents Chemother.52(12), 4388–4399 (2008).
   PubMed Web of Science ®Google Scholar
• Rahal JJ. Antimicrobial resistance among and therapeutic options against gram-negative pathogens. Clin. Infect. Dis.49(Suppl. 1), S4–S10 (2009).
   PubMed Web of Science ®Google Scholar
• Livermore DM. Doripenem: antimicrobial profile and clinical potential. Diagn. Microbiol. Infect. Dis.63(4), 455–458 (2009).
   PubMedGoogle Scholar
• Castanheira M, Jones RN, Livermore DM. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp. Diagn. Microbiol. Infect. Dis.63(4), 426–433 (2009).
   PubMed Web of Science ®Google Scholar
• Higgins PG, Wisplinghoff H, Stefanik D, Seifert H. In vitro activities of the β-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with β-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains. Antimicrob. Agents Chemother.48(5), 1586–1592 (2004).
   PubMed Web of Science ®Google Scholar
• Akova M. Sulbactam-containing β-lactamase inhibitor combinations. Clin. Microbiol. Infect.14(Suppl. 1), 185–188 (2008).
   PubMedGoogle Scholar
• Montero A, Ariza J, Corbella X et al. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J. Antimicrob. Chemother.54(6), 1085–1091 (2004).
   PubMed Web of Science ®Google Scholar
• Kuo LC, Lai CC, Liao CH et al. Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome. Clin. Microbiol. Infect.13(2), 196–198 (2007).
   PubMed Web of Science ®Google Scholar
• Sayin KS, Sacar S, Suzer T et al. [Successful treatment of a patient with multidrug resistant Acinetobacter baumannii meningitis with high dose ampicillin-sulbactam]. Mikrobiyol. Bul.42(2), 353–358 (2008).
   PubMedGoogle Scholar
• Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J. Infect.56(6), 432–436 (2008).
   PubMed Web of Science ®Google Scholar
• Ko WC, Lee HC, Chiang SR et al.In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain. J. Antimicrob. Chemother.53(2), 393–395 (2004).
   PubMed Web of Science ®Google Scholar
• Scheetz MH, Qi C, Warren JR et al.In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. Antimicrob. Agents Chemother.51(5), 1621–1626 (2007).
   PubMed Web of Science ®Google Scholar
• Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect. Dis.8(12), 751–762 (2008).
   PubMed Web of Science ®Google Scholar
• Akers KS, Mende K, Yun HC et al. Tetracycline susceptibility testing and resistance genes in isolates of Acinetobacter baumannii–Acinetobacter calcoaceticus complex from a U.S. military hospital. Antimicrob. Agents Chemother.53(6), 2693–2695 (2009).
   PubMed Web of Science ®Google Scholar
• Peleg AY, Adams J, Paterson DL. Tigecycline efflux as a mechanism for nonsusceptibility in Acinetobacter baumannii. Antimicrob. Agents Chemother.51(6), 2065–2069 (2007).
   PubMed Web of Science ®Google Scholar
• Principe L, D’Arezzo S, Capone A, Petrosillo N, Visca P. In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii. Ann. Clin. Microbiol. Antimicrob.8, 18 (2009).
   PubMed Web of Science ®Google Scholar
• Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J. Antimicrob. Chemother.62(1), 45–55 (2008).
   PubMed Web of Science ®Google Scholar
• Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E. Clinical and microbiological outcomes of serious infections with multidrug-resistant Gram-negative organisms treated with tigecycline. Clin. Infect. Dis.46(4), 567–570 (2008).
   PubMed Web of Science ®Google Scholar
• Deamer RL, Dial LK. The evolution of aminoglycoside therapy: a single daily dose. Am. Fam. Physician53(5), 1782–1786 (1996).
   PubMed Web of Science ®Google Scholar
• Doi Y, Husain S, Potoski BA, McCurry KR, Paterson DL. Extensively drug-resistant Acinetobacter baumannii. Emerg. Infect. Dis.15(6), 980–982 (2009).
   PubMed Web of Science ®Google Scholar
• Adams MD, Nickel GC, Bajaksouzian S et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob. Agents Chemother.53(9), 3628–3634 (2009).
   PubMed Web of Science ®Google Scholar
• Barrow K, Kwon DH. Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother.53(12), 5150–5154 (2009).
   PubMed Web of Science ®Google Scholar
• Cooperstock MS. Inactivation of endotoxin by polymyxin B. Antimicrob. Agents Chemother.6(4), 422–425 (1974).
   PubMed Web of Science ®Google Scholar
• Morrison DC, Jacobs DM. Inhibition of lipopolysaccharide-initiated activation of serum complement by polymyxin B. Infect. Immun.13(1), 298–301 (1976).
   PubMed Web of Science ®Google Scholar
• Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant Gram-negative bacteria. Ann. Pharmacother.33(9), 960–967 (1999).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin. Infect. Dis.40(9), 1333–1341 (2005).
   PubMed Web of Science ®Google Scholar
• Giamarellou H, Antoniadou A, Kanellakopoulou K. Acinetobacter baumannii: a universal threat to public health? Int. J. Antimicrob. Agents32(2), 106–119 (2008).
   PubMed Web of Science ®Google Scholar
• Munoz-Price LS, Weinstein RA. Acinetobacter infection. N. Engl. J. Med.358(12), 1271–1281 (2008).
   PubMed Web of Science ®Google Scholar
• Li J, Turnidge J, Milne R, Nation RL, Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother.45(3), 781–785 (2001).
   PubMed Web of Science ®Google Scholar
• Conway SP, Etherington C, Munday J, Goldman MH, Strong JJ, Wootton M. Safety and tolerability of bolus intravenous colistin in acute respiratory exacerbations in adults with cystic fibrosis. Ann. Pharmacother.34(11), 1238–1242 (2000).
   PubMed Web of Science ®Google Scholar
• Hartzell JD, Neff R, Ake J et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin. Infect. Dis.48(12), 1724–1728 (2009).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Rafailidis PI. Nephrotoxicity of colistin: new insight into an old antibiotic. Clin. Infect. Dis.48(12), 1729–1731 (2009).
   PubMed Web of Science ®Google Scholar
• Montero M, Horcajada JP, Sorli L et al. Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. Infection37(5), 461–465 (2009).
   PubMed Web of Science ®Google Scholar
• D’Agata EM. Rapidly rising prevalence of nosocomial multidrug-resistant, Gram-negative bacilli: a 9-year surveillance study. Infect. Control Hosp. Epidemiol.25(10), 842–846 (2004).
   PubMedGoogle Scholar
• Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob. Agents Chemother.47(5), 1681–1688 (2003).
   PubMed Web of Science ®Google Scholar
• Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am. J. Med.87(5), 540–546 (1989).
   PubMed Web of Science ®Google Scholar
• Montero A, Ariza J, Corbella X et al. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J. Antimicrob. Chemother.54(6), 1085–1091 (2004).
   PubMed Web of Science ®Google Scholar
• Saballs M, Pujol M, Tubau F et al. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. J. Antimicrob. Chemother.58(3), 697–700 (2006).
   PubMed Web of Science ®Google Scholar
• Timurkaynak F, Can F, Azap OK, Demirbilek M, Arslan H, Karaman SO. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int. J. Antimicrob. Agents27(3), 224–228 (2006).
   PubMed Web of Science ®Google Scholar
• Motaouakkil S, Charra B, Hachimi A et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J. Infect.53(4), 274–278 (2006).
   PubMed Web of Science ®Google Scholar
• Bassetti M, Repetto E, Righi E et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J. Antimicrob. Chemother.61(2), 417–420 (2008).
   PubMed Web of Science ®Google Scholar
• Tascini C, Gemignani G, Ferranti S et al. Microbiological activity and clinical efficacy of a colistin and rifampin combination in multidrug-resistant Pseudomonas aeruginosa infections. J. Chemother.16(3), 282–287 (2004).
   PubMed Web of Science ®Google Scholar
• Aoki N, Tateda K, Kikuchi Y et al. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. J. Antimicrob. Chemother.63(3), 534–542 (2009).
   PubMed Web of Science ®Google Scholar
• Ullman MA, Hovde LB, Rotschafer JC. The advantage of using sequential exposure to colistin sulfate (C) and meropenem (M) to combat carbapenem-resistant Pseudomonas aeruginosa (CRP). Presented at: 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, USA, 12–15 September 2009.
   Google Scholar
• Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin–tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin. Infect. Dis.44(3), 357–363 (2007).
   PubMed Web of Science ®Google Scholar
• Capitano B, Nicolau DP, Potoski BA et al. Meropenem administered as a prolonged infusion to treat serious Gram-negative central nervous system infections. Pharmacotherapy24(6), 803–807 (2004).
   PubMed Web of Science ®Google Scholar
• Li C, Du X, Kuti JL, Nicolau DP. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob. Agents Chemother.51(5), 1725–1730 (2007).
   PubMed Web of Science ®Google Scholar
• Lorente L, Lorenzo L, Martin MM, Jimenez A, Mora ML. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to Gram-negative bacilli. Ann. Pharmacother.40(2), 219–223 (2006).
   PubMed Web of Science ®Google Scholar
• Hendlin D, Stapley EO, Jackson M et al. Phosphonomycin, a new antibiotic produced by strains of streptomyces. Science166(901), 122–123 (1969).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kastoris AC, Karageorgopoulos DE, Rafailidis PI. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int. J. Antimicrob. Agents34(2), 111–120 (2009).
   PubMed Web of Science ®Google Scholar
• El Solh AA, Alhajhusain A. Update on the treatment of Pseudomonas aeruginosa pneumonia. J. Antimicrob. Chemother.64(2), 229–238 (2009).
   PubMed Web of Science ®Google Scholar
• Shah PM. Parenteral carbapenems. Clin. Microbiol. Infect.14(Suppl. 1), 175–180 (2008).
   PubMedGoogle Scholar
• Baum EZ, Crespo-Carbone SM, Morrow BJ et al. Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa. Antimicrob. Agents Chemother.53(7), 2785–2790 (2009).
   PubMedGoogle Scholar
• Abrahamian FM, Deblieux PM, Emerman CL et al. Health care-associated pneumonia: identification and initial management in the ED. Am. J. Emerg. Med.26(6 Suppl.), 1–11 (2008).
   PubMedGoogle Scholar
• Mesaros N, Nordmann P, Plesiat P et al.Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin. Microbiol. Infect.13(6), 560–578 (2007).
   PubMed Web of Science ®Google Scholar
• Baer M, Sawa T, Flynn P et al. An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity. Infect. Immun.77(3), 1083–1090 (2009).
   PubMed Web of Science ®Google Scholar
• Schmidtchen A, Pasupuleti M, Morgelin M et al. Boosting antimicrobial peptides by hydrophobic oligopeptide end tags. J. Biol. Chem.284(26), 17584–17594 (2009).
   PubMed Web of Science ®Google Scholar